Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.

doi:10.1158/1078-0432.CCR-10-2102

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 May 2011

Rizvi Naiyer A, Rusch Valerie, Pao William, Chaft Jamie E, Ladanyi Marc, Miller Vincent A, Krug Lee M, Azzoli Christopher G, Bains Manjit, Downey Robert, Flores Raja, Park Bernard, Singh Bhuvanesh, Zakowski Maureen, Heelan Robert T, Shen Ronglai, Kris Mark G

Abstract excerpt

PURPOSE: To determine if tumor regression following treatment with gefitinib correlates with the presence of sensitizing mutations in epidermal growth factor receptor (EGFR). PATIENTS AND METHODS: Patients with resectable stage I and II non-small cell lung cancer (NSCLC) enriched for the likelihood of EGFR mutation (≤ 15 pack-year cigarette smoking history and/or a component of bronchioloalveolar carcinoma)...

Topics

Adult
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung
Catalytic Domain
Drug Resistance, Neoplasm
ErbB Receptors
Female

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Gefitinib

Genes, erbB-1

Humans

Lung Neoplasms

Male

Middle Aged

Mutation

Prognosis

Protein Binding

Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 21558399
DOI: 10.1158/1078-0432.CCR-10-2102
PMCID: PMC3261615

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-21558399-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.PMID 21558399Read ↗

Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer.Semantic proximity Read ↗

Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.Semantic proximity Read ↗

A systems pathology model for predicting overall survival in patients with refractory, advanced non-small-cell lung cancer treated with gefitinib.Semantic proximity Read ↗

Histoculture drug response assay for gefitinib in non-small-cell lung cancer.Semantic proximity Read ↗

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.Semantic proximity Read ↗

Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.Semantic proximity Read ↗

Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.Semantic proximity Read ↗

EGFR mutations in non-small cell lung carcinomas may predict response to gefitinib: extension of an emerging paradigm.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.